Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study.

Date publication

avril 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique

Tous les auteurs :
Quesada S, Puszkiel A, Jouinot A, Thomas R, Kalbacher E, Follana P, Hardy-Bessard AC, Brachet PE, Combe P, Selle F, Lebreton C, Fournel P, Mille D, Alexandre J, Grellety T, Emambux S, Le Roux D, Spaeth D, Fabbro M, Joly F, Blanchet B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40220450

Résumé

Interindividual variability in pharmacokinetics may influence clinical outcomes of niraparib in patients with platinum-sensitive recurrent ovarian cancer (ROC). We aimed to investigate the pharmacokinetic-pharmacodynamic (PK-PD) relationship of niraparib in 49 patients with ROC from the multicenter phase IV NiQoLe study.

Mots clés

PK–PD relationship, drug monitoring, maintenance, niraparib, ovarian cancer, toxicity

Référence

ESMO Open. 2025 04 11;10(5):105054